Get started
Author

Jean‐Paul Castaigne

Observed names: J P Castaigne, J. P. Castaigne, J.-P. Castaigne, J.P. Castaigne, Jean-Paul Castaigne, Jean-Paul Castaigne, MD
OpenAlex ID: A5113719657
Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2
2008 · Michel Demeule, Jean‐Christophe Currie, et al. · Journal of Neurochemistry · 557
Identification and Design of Peptides as a New Drug Delivery System for the Brain
2007 · Michel Demeule, Anthony Régina, et al. · Journal of Pharmacology and Experimental Therapeutics · 464
Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate
2003 · Jung-Guk Kim, Laurie L. Baggio, et al. · Diabetes · 210
Prolonged Action of a Chimeric Interleukin-2 Receptor (cd25) Monoclonal Antibody Used in Cadaveric Renal Transplantation
1995 · Peter L. Amlot, Eira Rawlings, et al. · Transplantation · 182
New Angiopep-Modified Doxorubicin (ANG1007) and Etoposide (ANG1009) Chemotherapeutics With Increased Brain Penetration
2010 · Christian Ché, Gaoqiang Yang, et al. · Journal of Medicinal Chemistry · 133
ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
2014 · Anthony Regina, Michel Demeule, et al. · Molecular Cancer Therapeutics · 117
Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties
2014 · Michel Demeule, Nicolas Beaudet, et al. · Journal of Clinical Investigation · 117
Transport characteristics of a novel peptide platform for CNS therapeutics
2009 · Yanick Bertrand, Jean‐Christophe Currie, et al. · Journal of Cellular and Molecular Medicine · 74
PDF
40th EASD Annual Meeting of the European Association for the Study of Diabetes
2004 · M. Veitenhansl, K. Stegner, et al. · Diabetologia · 66
Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7–36) analog
2004 · Roger Léger, Karen Thibaudeau, et al. · Bioorganic & Medicinal Chemistry Letters · 62
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
2006 · Sam L. Teichman, Ann Neale, et al. · The Journal of Clinical Endocrinology & Metabolism · 48
Synthesis and Evaluation of Insulin−Human Serum Albumin Conjugates
2005 · Karen Thibaudeau, Roger Léger, et al. · Bioconjugate Chemistry · 47
Erythropoietin Treatment in Anaemic Patients on Haemodialysis
1986 · B. Zins, T. Drüeke, et al. · The Lancet · 46
A Phase II, multicenter, randomized, double-blind, placebo-controlled crossover study of CJC-1008—a long-acting, parenteral opioid analgesic—in the treatment of postherpetic neuralgia
2006 · Mark S. Wallace, MD, Dwight Moulin, MD, et al. · Journal of Opioid Management · 24
PDF
Recombinant Erythropoietin and Blood Pressure
1987 · Ch.J. Acquot, M. Ferragu-Haguet, et al. · The Lancet · 24
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
2006 · Maria Alba, Danilo Fintini, et al. · American Journal of Physiology-Endocrinology and Metabolism · 19
Synthesis and in vitro analysis of atrial natriuretic peptide–albumin conjugates
2003 · Roger Léger, Martin Robitaille, et al. · Bioorganic & Medicinal Chemistry Letters · 17
Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects
2008 · R.G. Tiessen, J.P. Castaigne, et al. · International Journal of Clinical Pharmacology and Therapeutics · 13
Evaluation of CNS and peripheral antitumor activity of ANG1005 in patients with brain metastases from breast tumors and other advanced solid tumors.
2014 · Nancy U. Lin, Nashat Y. Gabrail, et al. · Journal of Clinical Oncology · 5
139 POSTER Enhanced drug delivery to brain tumors with a new paclitaxel-peptide conjugate
2008 · F. Bichat, M. Demeule, et al. · European Journal of Cancer Supplements · 4
Addition of Desmopressin to Recombinant Human Erythropoietin in Treatment of Haemostatic Defect of Uraemia
1988 · Ch Jacquot, J.P. Masselot, et al. · The Lancet · 4
Experimental Therapeutics and Pharmacology
2013 · C. Aaberg-Jessen, L. Fogh, et al. · Neuro-Oncology · 3
PDF
Abstract 2465: Targeting HER2-positive brain metastases by incorporating the brain-penetrant Angiopep-2 peptide to an anti-HER2 antibody and anti-HER2 antibody drug conjugate
2015 · Michel Demeule, Sanjoy Das, et al. · Cancer Research · 2
Abstract 864: ANG4043: A new brain-penetrant peptide-antibody conjugate that reduces tumor growth in a HER2-positive orthotopic tumor model.
2013 · Jean E. Lachowicz, Michel Demeule, et al. · Cancer Research · 2
Abstract B49: GRN1005 phase I studies: Final results.
2011 · Patrick Y. Wen, Jan Drappatz, et al. · Molecular Cancer Therapeutics · 2
Works count: 51
Citation count: 2,253
H-index: 17
I10-index: 18
Year
Topic
Type